What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide fragment derived from a protein isolated in human gastric juice. It was first identified and studied by Croatian researcher Predrag Sikiric and his team, and has since accumulated an extensive body of animal-model research spanning gut healing, tendon repair, bone regeneration, neurological protection, and systemic anti-inflammatory effects.
The peptide is notable for its exceptional oral and systemic stability relative to most peptides. In animal studies, BPC-157 has consistently demonstrated the ability to accelerate healing of tendons, ligaments, muscles, and bone. It appears to work partly by upregulating growth hormone receptors in damaged tissue and by promoting angiogenesis (new blood vessel formation) through nitric oxide pathways and VEGF modulation.
BPC-157 also shows profound effects on the gut-brain axis. Animal models show protection against NSAID-induced gut damage, promotion of intestinal anastomosis healing, and reversal of drug-induced dyskinesia and dopamine system disruption. These properties make it a subject of interest for inflammatory bowel conditions and neuroprotection research.
It is important to note that no peer-reviewed human clinical trial data currently exists for BPC-157. All evidence for its benefits in humans is extrapolated from animal research and anecdotal reports from the research community. The peptide is not FDA-approved and is classified as a research compound only.
Research Supply
Source high-purity BPC-157 for your research
Dosage Guide
Route: Subcutaneous or intramuscular injection; oral administration under investigation
Dosing Schedule
| Period | Dose |
|---|---|
| Standard research dose | 200-400 mcg (0.2-0.4 mg) per day |
| Higher research dose | 500-1000 mcg (0.5-1.0 mg) per day |
| Divided dosing | Split into two injections of 100-250 mcg, AM and PM |
| Typical cycle length | 4-12 weeks on, 4 weeks off |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 200 mcg | 0.10 mL | 10 units |
| 250 mcg | 0.125 mL | 12.5 units |
| 400 mcg | 0.20 mL | 20 units |
| 500 mcg | 0.25 mL | 25 units |
Cycling Protocol
4-12 weeks of daily use
4 weeks minimum off period
BPC-157 does not appear to cause hormonal suppression or significant receptor downregulation in animal studies, but research-use cycling protocols typically include off periods to allow assessment of baseline healing status and to reduce unknowns associated with prolonged use of an unstudied compound in humans.
Local vs. Systemic Injection
LOCAL INJECTION
Inject subcutaneously directly adjacent to the injured area (e.g., near a damaged tendon, joint capsule, or muscle belly). This is the preferred method for localized tissue injuries where direct tissue exposure is desired. Some researchers use intramuscular injection near the injury site for deeper tissue access.
SYSTEMIC INJECTION
Inject subcutaneously in the lower abdomen. This is the standard approach for gut-related applications (IBD, leaky gut, NSAID-induced damage), neurological effects, or when treating multiple sites simultaneously. Systemic delivery still appears effective for musculoskeletal healing based on animal studies.
Administration Tips
- Use bacteriostatic water (not sterile water) for reconstitution to extend shelf life to 30 days refrigerated
- For localized injury (tendon, muscle, joint): inject subcutaneously near the site of injury
- For systemic effects (gut, brain, general healing): inject subcutaneously in the abdomen
- Administer consistently at the same times each day for stable plasma levels
- Store lyophilized (unmixed) vials at -20C for up to 24 months; at room temperature for up to 3 months
- Store reconstituted solution refrigerated at 2-8C and use within 30 days
- Use a 29-31 gauge insulin syringe; inject slowly to minimize site discomfort
Risks & Side Effects
Commonly Reported
Serious Risks
Unknown long-term effects
No human clinical trials exist. Long-term effects in humans are completely unknown. Use carries inherent unknown risk by definition.
Angiogenesis promotion
BPC-157 promotes new blood vessel formation. While beneficial for healing, this property theoretically raises concern in individuals with existing neoplastic (cancer) conditions, as new vasculature could support tumor growth.
Drug interactions
BPC-157 modulates dopamine, serotonin, and GABA systems in animal models. Interactions with psychotropic medications, opioids, and anticoagulants have not been formally studied in humans.
Immune modulation
Anti-inflammatory properties may mask symptoms of underlying infection or injury. Pain suppression could delay identification of serious conditions requiring medical intervention.
Contraindications
- Active cancer or history of malignancy (theoretical concern due to angiogenic properties)
- Pregnancy or breastfeeding
- Known hypersensitivity to BPC-157 or any excipient
- Use in children or adolescents (no safety data)
- Concurrent use with anticoagulants without medical supervision
Frequently Asked Questions
Related Peptides
Experts Covering BPC-157
Dr. William A. Seeds
MD -- Regenerative Medicine Pioneer
Dr. Andrew Huberman
PhD -- Stanford Neuroscientist
Jay Campbell
Health Optimization Author and Peptide Advocate
Dr. Ian W. Hamley
Diamond Professor of Physical Chemistry -- University of Reading
Matthew Farrahi
Biohacker, CEO of Sigma Compounds, and Fitness Creator
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. BPC-157 is a research compound that has not been approved by the FDA or any regulatory authority for human use. No human clinical trial data exists for this compound. All referenced benefits are derived from animal studies and should not be interpreted as proven human effects. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.